$27.46
-1.01[-3.55%]
At close: Apr 25
$27.46
0[0.00%]
After Hours: 4:00PM EDT
Genmab Stock (NASDAQ:GMAB), Analyst Ratings, Price Targets, Predictions
Genmab A/S has a consensus price target of $27.75, established from looking at the 64 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Morgan Stanley on April 4, 2024, March 27, 2024, and March 26, 2024. With an average price target of $44 between HC Wainwright & Co., HC Wainwright & Co., and Morgan Stanley, there's an implied 60.23% upside for Genmab A/S from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Morgan Stanley
Truist Securities
BMO Capital
BTIG
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Genmab
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/04/2024 | GMAB | Buy Now | Genmab | $27.46 | 82.08% | HC Wainwright & Co. | Raghuram Selvaraju | → $50 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | GMAB | Buy Now | Genmab | $27.46 | 82.08% | HC Wainwright & Co. | Raghuram Selvaraju | $50 → $50 | Maintains | Buy | Get Alert |
| 03/26/2024 | GMAB | Buy Now | Genmab | $27.46 | 16.53% | Morgan Stanley | Matthew Harrison | $32 → $32 | Maintains | Underweight | Get Alert |
| 03/26/2024 | GMAB | Buy Now | Genmab | $27.46 | 82.08% | Truist Securities | Asthika Goonewardene | $50 → $50 | Maintains | Buy | Get Alert |
| 03/06/2024 | GMAB | Buy Now | Genmab | $27.46 | 82.08% | HC Wainwright & Co. | Raghuram Selvaraju | → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | GMAB | Buy Now | Genmab | $27.46 | 74.8% | BMO Capital | Etzer Darout | $46 → $48 | Upgrade | Market Perform → Outperform | Get Alert |
| 02/20/2024 | GMAB | Buy Now | Genmab | $27.46 | 82.08% | Truist Securities | Asthika Goonewardene | $54 → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/20/2024 | GMAB | Buy Now | Genmab | $27.46 | 82.08% | HC Wainwright & Co. | Raghuram Selvaraju | → $50 | Reiterates | Buy → Buy | Get Alert |
| 01/29/2024 | GMAB | Buy Now | Genmab | $27.46 | 82.08% | HC Wainwright & Co. | Raghuram Selvaraju | $49 → $50 | Maintains | Buy | Get Alert |
| 11/28/2023 | GMAB | Buy Now | Genmab | $27.46 | 78.44% | HC Wainwright & Co. | Raghuram Selvaraju | → $49 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | GMAB | Buy Now | Genmab | $27.46 | 78.44% | HC Wainwright & Co. | Raghuram Selvaraju | → $49 | Reiterates | Buy → Buy | Get Alert |
| 11/09/2023 | GMAB | Buy Now | Genmab | $27.46 | 16.53% | Morgan Stanley | Matthew Harrison | $33 → $32 | Maintains | Underweight | Get Alert |
| 11/08/2023 | GMAB | Buy Now | Genmab | $27.46 | 78.44% | HC Wainwright & Co. | Raghuram Selvaraju | $51 → $49 | Maintains | Buy | Get Alert |
| 10/18/2023 | GMAB | Buy Now | Genmab | $27.46 | 85.72% | HC Wainwright & Co. | Raghuram Selvaraju | → $51 | Reiterates | Buy → Buy | Get Alert |
| 10/13/2023 | GMAB | Buy Now | Genmab | $27.46 | 67.52% | BTIG | Kaveri Pohlman | $44 → $46 | Maintains | Buy | Get Alert |
| 09/26/2023 | GMAB | Buy Now | Genmab | $27.46 | 96.65% | Truist Securities | Asthika Goonewardene | → $54 | Reiterates | Buy → Buy | Get Alert |
| 09/06/2023 | GMAB | Buy Now | Genmab | $27.46 | 96.65% | Truist Securities | Asthika Goonewardene | → $54 | Reiterates | Buy → Buy | Get Alert |
| 09/05/2023 | GMAB | Buy Now | Genmab | $27.46 | 85.72% | HC Wainwright & Co. | Raghuram Selvaraju | → $51 | Reiterates | Buy → Buy | Get Alert |
| 08/24/2023 | GMAB | Buy Now | Genmab | $27.46 | 60.23% | BTIG | Kaveri Pohlman | → $44 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Genmab (GMAB)?
The latest price target for Genmab (NASDAQ: GMAB) was reported by HC Wainwright & Co. on April 4, 2024. The analyst firm set a price target for $50.00 expecting GMAB to rise to within 12 months (a possible 82.08% upside). 37 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Genmab (GMAB)?
The latest analyst rating for Genmab (NASDAQ: GMAB) was provided by HC Wainwright & Co., and Genmab reiterated their buy rating.
When was the last upgrade for Genmab (GMAB)?
The last upgrade for Genmab A/S happened on February 23, 2024 when BMO Capital raised their price target to $48. BMO Capital previously had a market perform for Genmab A/S.
When was the last downgrade for Genmab (GMAB)?
The last downgrade for Genmab A/S happened on January 3, 2022 when Guggenheim changed their price target from N/A to N/A for Genmab A/S.
When is the next analyst rating going to be posted or updated for Genmab (GMAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Genmab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Genmab was filed on April 4, 2024 so you should expect the next rating to be made available sometime around April 4, 2025.
Is the Analyst Rating Genmab (GMAB) correct?
While ratings are subjective and will change, the latest Genmab (GMAB) rating was a reiterated with a price target of $0.00 to $50.00. The current price Genmab (GMAB) is trading at is $27.46, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.